<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="498157" id="root" date="1997-04-09" xml:lang="en">
<title>UK: Oxford Molecular progress on cancer antibody.</title>
<headline>Oxford Molecular progress on cancer antibody.</headline>
<dateline>LONDON 1997-04-09</dateline>
<text>
<p>Britain's Oxford Molecular Group said on Wednesday that it had completed a collaboration to humanise the C242 monoclonal antibody for potential use in anticancer phamaceuticals to treat colorectal cancer.  </p>
<p>Oxford Molecular said it had signed the collaboration with ImmunoGen Inc and would have exclsuive rights to its resurfacing technology.</p>
<p>Immunogen holds all rights to this potential oncology drug and would be responsible for product development and commercialisation for treatment of colorectal cancer.</p>
<p>Oxford Molecular said the combination of its molecular modelling software with ImmunoGen's technology would be a powerful tool for humanising monoclonal antibodies.</p>
<p>Monoclonal antibodies are proteins that bind specifically to unique markers called antigens, often found on the surface of cells.</p>
<p>Immunogen had received permission from U.S. authorities last January for the antibody resurfacing technology which is a method that makes mouse monoclonal antibodies appear human to the body's immune system.</p>
<p>Without humanisation, the immune system recognises mouse antibodies as foreign and would reject them.</p>
<p>The technology was codeveloped by Immunogen scientists and Anthony Rees, a founding director of Oxford Molecular.</p>
<p>--London Newsroom +44 171 542 4366</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="UK">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
  <code code="I33020">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
  <code code="I3302021">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
  <code code="C33">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1997-04-09"/>
  </code>
</codes>
<dc element="dc.date.created" value="1997-04-09"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1997-04-09"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="LONDON"/>
<dc element="dc.creator.location.country.name" value="UK"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
